Viridian Therapeutics, Inc./DE Accumulated Other Comprehensive Income
Viridian Therapeutics, Inc./DE (VRDN) had Accumulated Other Comprehensive Income of -$1.15 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.15M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$558.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $447.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $363.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$1.15M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$558.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | $447.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $363.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $69.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $245.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$10.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $932.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$543.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$367.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $338.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | -$64.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$173.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$174.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | -$390.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | -$940.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$1.08M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$935.00K 10-Q · filed 2022-05-13 |
| 2021-12-31 | -$157.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | -$3.00K 10-Q · filed 2021-11-05 |
| 2021-06-30 | -$12.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$21.00K 10-Q · filed 2021-05-07 |
| 2020-12-31 | -$8.00K 10-K · filed 2022-03-11 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-26 |
| 2019-09-30 | $3.00K 10-Q · filed 2019-11-08 |
| 2019-06-30 | $11.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $2.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | -$3.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | -$6.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $4.00K 10-Q · filed 2018-08-08 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |